25th – 27th February, 2025
London, UK

8th Annual
Europe CAR-TCR Summit

Trailblazing Next-Gen Cell Therapies in Autoimmunity & Solid Tumours

Enhance Engineering to Improve Durability & Cell Function, with Advanced Manufacturability to Consistently Develop Affordable, Efficacious Cell Therapies

50+ World-Class Speakers, Including:

So-ching Brazer
Executive Director, Regulatory Affairs
Adicet Bio

Marlene Carrasco Alfonso
Global Clinical Head Immunology Cell Therapy
AstraZeneca

Rhine Shen
Senior Director, Translational Medicine
Kite, A Gilead Company

Gwendolyn Binder
President, Science & Technology
Cabaletta Bio

Frederik De Vos
Senior Director, Quality Operations
Johnson & Johnson

Ali Mohamed
Senior Vice President, Chemistry, Manufacturing & Controls
Immatics

Birk Vanderween
Senior Vice President, Global Manufacturing & Supply
Legend Biotech

Proud to Partner With:

Catalent CELL & GENE THERAPY

Miltenyi Biotec

TERUMO BLOOD AND CELL TECHNOLOGIES

VIROCELL BIOLOGICS

www.cartcr-europe.com **Tel:** +44 (0)20 3141 8700 **Email:** info@hansonwade.com CAR-TCR Summit Series @CAR_TCell

hansonwade

Welcome to the 8th CAR-TCR Summit Europe

With the recent financial success from Kyverna and Artiva who announced their IPOs in the last few months; ArsenalBio's huge investment success, and Adaptimmune's recent approval in TCR for solid tumours, hope is returning to the cell therapy field. The continued need to innovate and improve cell therapy clinical results across solid tumours and autoimmune diseases remains a critical priority for the community, to deliver on the promise of cell therapies for patients globally.

Back for the 8th year, the **CAR-TCR Summit Europe** returns as the go-to forum exclusively showcasing the hottest innovation across the entire process of cell therapy discovery and development, with the shared mission to consistently develop complex therapies which can achieve durable responses in a time and cost-efficient manner.

Across three dedicated tracks of content, attend with your team to stay ahead of the curve:

- **Discovery -** Uncover novel engineering approaches and targets to improve cell fitness, durability and potency in solid tumours, haematological malignancies and autoimmune indications
- **Clinical Development -** Showcase translational learnings, best practice for clinical trial design and interesting clinical data to ensure successful and cost-efficient trials
- **CMC, Process & Analytics -** Advancing the manufacturability, quality control and engineering of complex cell therapies in early development with commercial scale and regulations in mind

We look forward to welcoming you to London this February where you can gain unmatched competitor intelligence on those trailblazing innovation and overcoming common challenges in development, and together move closer to delivering the curative promise of cell therapies in oncology and autoimmune disease.

Saachi Mody
Senior Programme Director – CAR-TCR Series
Hanson Wade

Key Agenda Highlights:

Address safety concerns with autoimmune indications and selecting the disease with the highest durability to reduce toxicity and improve efficacy with **Cabaletta Bio**

Break down the barriers and improve regulatory engagement and communication to tailor guidelines and gain regulatory support with **Sana Biotechnology**

Understand novel engineering technologies such as gene editing and armouring to improve durability and persistence with **T-knife Therapeutics**

Explore the differences in manufacturing processes for novel cell types to improve robustness of process and finetune manufacturing conditions with **Eli Lilly**

Gain a holistic understanding of the cancer environment using multiple tumour models to improve patient selection and clinical trial success with **Kite, A Gilead Company**

"The 8th CAR-TCR Summit Europe is the premier conference of its kind and the best place to catch up on all developments in the space and network with global leaders in the space"

Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics

50+ Expert Speaker Faculty

8th Annual Europe CAR-TCR Summit

25th – 27th February, 2025 | London, UK

Blake Aftab
Chief Scientific Officer
Adicet Bio

So-ching Brazer
Executive Director, Regulatory Affairs
Adicet Bio

Rob Margolin
Vice President, Commercial
Akron Biotech

Cécile Bauche
Chief Scientific Officer, Co-Founder
Alaya.bio

Renaud Vaillant
Chief Executive Officer
Alaya.bio

Maria E. Alonso-Ferrero
Immunogenicity Sciences, Cell Therapy TA Lead
Alexion Pharmaceuticals

Hugh Salter
Chief Scientific Officer
Anocca

Karin Enarsson Ringqvist
Senior Clinical Program Director
AstraZeneca

Marlene Carrasco Alfonso
Global Clinical Head Immunology Cell Therapy
AstraZeneca

Hemant Dhamne
Associate Director, Process Development
Autolus

Rachel East
Research Analyst
Beacon

Houman Dehghani
Vice President, Process & Analytical Development
Cabaletta Bio

Jenell Volkov
Senior Director, Translational Medicine
Cabaletta Bio

Gwendolyn Binder
President, Science & Technology
Cabaletta Bio

Felix Lorenz
Chief Executive Officer/ Chief Scientific Officer
Captain T Cell

Nuria Gomez Santos
Director Process and Analytical Development
Catalent Cell and Gene Therapy

Laurent Poirot
Senior Vice President, Immunology
Cellectis

Jeffrey Jones
Chief Medical Officer
Cullinan Therapeutics

Kerstin Papenfuss
Head Pharma Team
Deep Science Ventures

Emilio Cosimo
Life Science Consultant
Emilio Cosimo Consulting

Bryan Zimdahl
Senior Director, Clinical Science & Regulatory Affairs
Eureka Therapeutics



Tiffany Chen
Vice President, Discovery
GentiBio

Shayoni Dutta
Data Science Manager
GSK

Allen Feng
Founder & Chief Scientific Officer
HebeCell

50+ Expert Speaker Faculty

Finola Cliffe
Chief Operations Officer
Hooke Bio

Ali Mohamed
Senior Vice President, Chemistry, Manufacturing & Controls
Immatics

Frederik De Vos
Senior Director, Quality Operations
Johnson & Johnson

Rhine Shen
Senior Director, Translational Medicine
Kite, A Gilead Company

Leon Spijkers
Chief Executive Officer
Korecyte Bio

Birk Vanderweeën
Senior Vice President, Global Manufacturing & Supply
Legend Biotech

John Maher
Chief Scientific Officer
Leucid Bio

Marc Davies
Vice President, Research & Development
Leucid Bio

Jeff Liter
Founder & Chief Executive Officer
Luminary Therapeutics



Omer Dushek
Founder
MatchBio

Raphael Ognar
President & Chief Executive Officer
NKILT Therapeutics

Bradley Delaney
Scientist I
Nona Biosciences

Michael Bauer
Partner
Novo Holdings Venture Investments

Stefanos Theoharis
Chief Executive Officer
OneChain Immunotherapeutics

Matthew Tridget
Senior Scientist, Viral Cell Line Development
OXGENE, A WuXi Advanced Therapies Company

Rupert Kenefeck
Senior Director, Translational Medicine
Quell Therapeutics



Katja Mohrs
Principal Scientist
Regeneron

Victor Dillard
Vice President, Strategy & Operations
Resolution Therapeutics



Deep Shah
Senior Director, Regulatory Affairs
Sana Biotechnology

Marion Jung
Chief Operating Officer
T-CURX

Peggy Sotiropoulou
Chief Scientific Officer
T-knife Therapeutics

Leopold Sellner
Senior Director
Takeda

Mindy Miller
Head of Cell Therapy Scientific Development
Terumo



Jiri Eitler
Group Leader
TU Dresden

50+ Expert Speaker Faculty

Pierre Springuel
PhD Candidate
UCL

David Fontana
Chief Operating Officer
Umoja Biopharma

George Coukos
Director
Ludwig Institute for Cancer Research Lausanne Branch

Rosa de Groot
PhD, Assistant Professor
Leiden University Medical Center, Department of Hematology

Rudolf Übelhart
Chief Scientific Officer
Vanudis

Farzin Farzaneh
Chief Scientific Officer & Co-Founder
Virocell Biologics

Luise Weigand
Head Of Research
Zelluna Immunotherapy

Advisory Board:

Blake Aftab
Chief Scientific Officer
Adicet Bio

Adrian Bot
Chief Scientific Officer
Capstan Therapeutics

Peggy Sotiropoulou
Chief Scientific Officer
T-knife Therapeutics

Leopold Sellner
Senior Director
Takeda

> "I think the focus on next generation engineering and CMC really makes this conference stand out. I also like the focus on autoimmunity as an emerging area of cell therapy"
>
> **Samik Basu, Chief Scientific Officer, Cabaletta Bio**

Autoimmune & Regulatory Focus Days | Tuesday, 25th February

8.00 Check-In & Morning Coffee

Autoimmune Focus Day

9.00 Chair's Opening Remarks

Chair: Tiffany Chen, Vice President, Discovery, **GentiBio**

9.10 Room Introduction

Take the chance to introduce yourself to your peers and make the most of this intimate networking opportunity before diving headfirst into a day focused on developing cell therapies for autoimmune indications

Addressing the Safety Concerns with Autoimmune Indications to Reduce Toxicities & Improve Efficacy

9.30 Development Progress & Opportunities for CAR-T in Autoimmune Disease

- Immune effectors for autoimmune disease
- Exploring the emerging data landscape for CAR-T in autoimmune indications
- Analysing the development considerations for autoimmune diseases

Gwendolyn Binder, President, Science & Technology, **Cabaletta Bio**

10.00 T-Cell Engagers in Autoimmune Diseases: An Alternative Approach for T-Cell Redirecting Therapy

- Emerging data supporting the safety and efficacy of TCEs to treat autoimmune disease
- Practical advantages of TCE vs CAR-T for T-cell redirecting therapy for autoimmune diseases
- Evolving TCE landscape: CD19 and beyond

Jeffrey Jones, Chief Medical Officer, **Cullinan Therapeutics**

Navigating Through Multiple Autoimmune Indications to Select the Disease with Highest Durability & Efficacy Data to Move the Needle Forward in Treating All Autoimmune Diseases

11.00 Developing TCR & CAR Targeted Engineered Treg Cells for Autoimmune Diseases

- Developing TCR targeted EngTreg GNTI-122 for Type 1 Diabetes
- CAR discovery for EngTreg therapy
- CAR EngTregs for other autoimmune diseases

Tiffany Chen, Vice President, Discovery, **GentiBio**

Regulatory Focus Day

9.00 Chair's Opening Remarks

Chair: David Fontana, Chief Operation Officer, **Umoja Biopharma**

9.10 Room Introduction

Take the chance to introduce yourself to your peers and make the most of this intimate networking opportunity before diving headfirst into a day focused on understanding and meeting regulatory expectations

Understanding How to Get Regulatory Approval to Carry Out Trials & Conduct Testing of Your Cell Therapy Product

9.30 Case Study: Hearing from a Successful IND Filing to Hone Regulatory Considerations & Get Approval to Conduct Clinical Trials

- Exploring regulatory guidelines and how to meet them
- Understanding the data required to get IND approval
- Reviewing steps taken to ensure successful IND filing

So-ching Brazer, Executive Director, Regulatory Affairs, **Adicet Bio**

10.00 Regulatory Insights & Best Practices for Advancing Autologous T-Cell Therapies in Early Clinical Stages

- CMC considerations to streamline IND development
- Navigating the ever-evolving regulatory landscape regarding product consistency
- Incorporating adaptive trial designs to further clinical program development

Bryan Zimdahl, Senior Director, Clinical Science & Regulatory Affairs, **Eureka Therapeutics**

10.30 Morning Networking Break

Gaining Regulatory Support to Understand the Way Forward & What Guidelines Need to be Met to Continue Progress in the Field

11.00 Breaking Down Barriers: An Effective Regulatory Engagement to Accelerate Innovation for ATMPs

- Proactive engagement and CMC leadership
- Risk management and education
- Tailored guidelines and timeline management

Deep Shah, Senior Director, Regulatory Affairs, **Sana Biotechnology**

Autoimmune & Regulatory Focus Days | Tuesday, 25th February

12.00 Panel Discussion: Assessing Autoimmune Disease Indications to Understand Which One to Select & How it Might Benefit from Cell Therapy

- Reviewing how to select the "correct" autoimmune indication
- Identifying what makes the "correct" autoimmune indication
- Exploring the true benefit of cell therapy on said indication

Jiri Eitler, Group Leader, **TU Dresden**

Maria E. Alonso-Ferrero, Immunogenicity Sciences, Cell Therapy TA Lead, **Alexion Pharmaceuticals**

12.00 Panel Discussion: Navigating the Regulatory Perspective on Novel & Different Approaches to Cell Therapy to Understand the Way Forward

- Understanding the regulatory perspective on cell engineering and armouring
- Exploring regulatory perspective on different cell types to make the smart choice
- Examining regulatory perspective on autologous therapy vs allogeneic therapy and how that affects your manufacturing processes

Deep Shah, Senior Director, Regulatory Affairs, **Sana Biotechnology**

Leon Spijkers, Chief Executive Officer, **Korecyte Bio**

So-ching Brazer, Executive Director, Regulatory Affairs, **Adicet Bio**

12.30 Networking Lunch

1.30 Audience Discussion: Analysing How to Show Durability of Response for Non-Life-Threatening Diseases to Convince Physicians to Dose Patients

- Exploring the hesitancy behind dosing patients and how to convince them
- Reviewing the best way to showcase strong durability of response
- Showcasing durability of response for off the shelf approaches

Use this time with your peers to discuss strategies for convincing physicians to utilise cell therapy for autoimmune indications

1.30 Audience Discussion: Discussing the Inclusion Criteria for Current & Novel Therapies to Confidently Conduct Clinical Trials

- Exploring how inclusion criteria affects patient recruitment
- Understanding how safety profile feeds into the inclusion criteria
- Overcoming narrow inclusion criteria to ensure accurate clinical trials

Use this time with your peers to discuss patient recruitment and inclusion criteria to ensure success in clinical trials

2.30 End of Autoimmune & Regulatory Focus Days & Start of Driving Diversity in CAR-TCR & C-Level Think Tank

Driving Diversity in CAR-TCR | Tuesday, 25th February

2.30 End of Autoimmune & Regulatory Focus Days

3.00 **Panel Discussion: Women in the Workplace**

Understanding the challenges faced by women in the workplace, the workplace experience as a woman and a woman in power and most importantly, how to ensure equal opportunities for women.

Peggy Sotiropoulou
Chief Scientific Officer
T-knife Therapeutics

Tiffany Chen
Vice President, Discovery
GentiBio

FREE TO ATTEND

5.00 **End of Diversity Session**

C-level Think Tank | Tuesday, 25th February

2.30 End of Autoimmune & Regulatory Focus Days

3.00 **C-level Think Tank**

An exclusive opportunity for top C-level executives from biotech and senior executives from pharma to collaborate and discuss the most pressing challenges the CAR-TCR community are facing in Europe. Run by experienced leaders Gwendolyn Binder and Raphaël Ognar, there will be no stone left unturned: join this discussion to share thought leadership on how to drive efficacies, boost safety, improve cost efficiency and unlock accessibility of cell therapies, to ultimately deliver durable CAR and TCR therapies to patients.

Gwendolyn Binder
President, Science & Technology
Cabaletta Bio

Raphaël Ognar
President & Chief Executive Officer
NKILT Therapeutics

FREE TO ATTEND INVITE ONLY

5.00 **End of C-level Think Tank**

> "Great networking with other biotech & pharma companies working in the CAR-TCR cell therapy space"
>
> **Rudolf Ubelhart, Chief Scientific Officer, Vanudis**

Scientific Programme Day One | Wednesday, 26th February

Key Oncology Autoimmune

7.30 Check-In & Morning Coffee

Saachi Mody
Senior Programme Director, CAR-TCR Series
Hanson Wade

8.30 **Welcome from the Programme Director**

Gwendolyn Binder
President, Science & Technology
Cabaletta Bio

8.35 **Chair's Opening Remarks**

Moving With the Field: Exploring the Way Forward to Turbocharge Cell Therapy Development & Be the Best in Class

8.45 **Industry Leaders Fireside Chat: Exploring the Different Approaches to Cell Therapy Development to Gain a Holistic Overview of the Field**

- Discussing exciting developments like approvals and commercialisations of TIL and TCR therapies for solid tumours and what it means for the field
- Looking towards gamma delta cells, NK cells, TIL therapies and more to target multiple autoimmune and cancer indications
- Identifying novel approaches to cell therapy development

Blake Aftab
Chief Scientific Officer
Adicet Bio

Leopold Sellner
Senior Director
Takeda

David Fontana
Chief Operating Officer
Umoja Biopharma

Ali Mohamed
Senior Vice President, Chemistry, Manufacturing & Controls
Immatics
NEW DATA

9.30 **Manufacturing of ACTengine® IMA203 to Support a Registration-Enabling Phase 3 Trial in Melanoma (SUPRAME)**

- IMA203 is an autologous TCR-T therapy targeting PRAME, an intracellular protein displayed as peptide antigen at high density on the surface of multiple solid tumors, including melanoma
- IMA203 delivers durable responses with favorable tolerability in melanoma patients with unmet medical needs, IMA203CD8 is a second-generation approach to expand PRAME-targeting TCR-T to other solid tumor types; recent clinical Phase 1 data will be presented
- In-house manufacturing for the supply of TCR-T products for early-stage and registration-enabling clinical trials

George Coukos
Director
Ludwig Institute for Cancer Research Lausanne Branch
NEW DATA

10.00 **Neoantigen Enriched TIL - Development & Clinical Application**

- Higher number of tumor-specific T cells in the therapeutic products is associated with clinical response in TIL therapy
- B-cell mediated costimulation markedly enhances the frequency and number of tumor specific TIL clones in the therapeutic products
- HLA loss is a key barrier to therapeutic success in TIL therapy

10.30 Morning Speed Networking Break

Scientific Programme Day One | Wednesday, 26th February

Discovery

Chair: Marc Davies, Vice President, Research & Development, **Leucid Bio**

Exploring Novel T-Cell Engineering Techniques to Improve Cell Fitness & Durability

11.30 Advanced TALEN Gene-Editing for Overcoming Barriers to the Success of CAR-T Cells in Solid Tumors

- Leveraging multiplexed TALEN gene-editing to expand the success of allogeneic CAR-T therapies from hematological malignancies to solid tumors
- Utilising TALEN® to perform targeted genome modifications to program inducible immune functions into therapeutic cells
- Developing several strategies to improve potency while preserving patient safety

Laurent Poirot, Senior Vice President, Immunology, **Cellectis**

12.00 Group Discussion: Triple Engineered T-Cells: Are They the Answer to Improved Durability & Persistence?

- Understanding what triple engineered T-cells are
- Analysing how triple engineering can improve durability and persistence
- Exploring what each step of engineering entails

12.30 Panel Discussion: Screening Through Multiple Armouring Technologies to Find the One Fit for Your Purpose

- Identifying the different armouring technologies
- Understanding how each technology differs and how to select the appropriate one
- Matching the required armouring technology to your cell therapy product

Peggy Sotiropoulou, Chief Scientific Officer, **T-Knife Therapeutics**

Raphaël Ognar, President & Chief Executive Officer, **NKILT Therapeutics**

Rudolf Übelhart, Chief Scientific Officer, **Vanudis**

Clinical Development

Chair: Rhine Shen, Senior Director, Translational Medicine, **Kite, A Gilead Company**

Translational Practices and Clinical Trial Set Up to Improve Data Readouts & Clinical Success

11.30 Bridging Preclinical Discoveries to Clinical Success in Cell Therapy

- Identifying Translational Gaps: Explore why promising preclinical findings often fail in clinical trials, focusing on biological limitations, regulatory hurdles, and patient selection challenges
- Strategies for Improved Translation: Using preclinical models, biomarkers, and early regulatory engagement to enhance predictability
- Case Studies & Future Directions: Showcase successful transitions and best practices for research, development, and manufacturing alignment

Emilio Cosimo, Life Science Consultant, **Emilio Cosimo Consulting**

12.00 Overcoming Challenges in Manufacturing: Insights from Two Distinct TCR-T Cell Clinical Projects

- TCR biology impacting the IMP production process
- Developing TCR specific QC

Rosa de Groot, PhD, Assistant Professor, **Leiden University Medical Center, Department of Hematology**

12.30 Panel Discussion: Rethinking the Considerations for Patient Selection to Ensure It Matches with the Indication You Are Targeting

- Analysing the patient guidelines for your cancer indication
- Translating standard patient selection guidelines to match your clinical trial goals
- Reflecting what patient guidelines are required to meet regulatory expectations

Hugh Salter, Chief Scientific Officer, **Anocca**

Rhine Shen, Senior Director, Translational Medicine, **Kite, A Gilead Company**

CMC, Process & Analytics

Chair: Rob Margolin, Vice President, Commercial, **Akron Biotech**

Optimising Manufacturing Processes for Next Generation Cell Therapies to Bring Down Vein to Vein Time

11.30 Pioneering Non-Viral CAR-T Technology to Democratize CAR-T Therapies

- Scalable and cost-effective non-viral transposon technology
- Enabling Point-of-Care, bedside or eventually in vivo CAR-T
- Clinical CAR-T pipeline in hematological and solid tumors

Marion Jung, Chief Operating Officer, **T-CURX**

12.00 Flexible Manufacturing for High-Quality T Cells: Tailored Solutions for Evolving Needs

- Expanding CAR-T cells to a therapeutic dose from very low starting cell numbers
- Tailor expansion parameters to increase Tscm frequency
- Utilising automated sensing to maintain optimal growth conditions

Mindy Miller, Head of Cell Therapy Scientific Development, **Terumo**

12.30 Panel Discussion: Centralised vs Decentralised Manufacturing: Assessing the Pros & Cons to Know the Best Way forward for Next-Generation Cell Therapies

- Investigating the use of decentralised manufacturing and its advantages
- Debating centralised vs decentralised manufacturing to understand which is fit for purpose
- Identifying the best option to turbocharge next-generation cell therapy development

Ali Mohamed, Senior Vice President, Chemistry, Manufacturing & Controls, **Immatics**

Birk Vanderweeën, Senior Vice President, Global Manufacturing & Supply, **Legend Biotech**

Scientific Programme Day One | Wednesday, 26th February

1.00 Networking Lunch

2.00 Transforming Cell & Gene Therapy from *Ex Vivo* to *In Situ*

- Description of our polymeric delivery platform to target and reprogram cells in situ
- In vitro and in vivo preliminary data showing the efficacy of the platform
- New targeting agents to increase the flexibility of the platform

Cécile Bauche, Chief Scientific Officer, Co-Founder, **Alaya.bio**

2.00 Roundtable Discussion: Educating Clinicians on the Benefits of Cell Therapy for Autoimmune Diseases to Recruit Patients & Ensure Trial Success

- Understanding the reason behind hesitance from clinicians to dose patients with cell therapy
- Explaining safety and efficacy of cell therapy treatment for autoimmune diseases
- Utilising the clinician's voice to recruit patient populations that match your clinical trial design

Leopold Sellner, Senior Director, **Takeda**

2.00 Group Discussion: Exploring the Differences in Manufacturability of Novel Cell Types to Fine Tune Manufacturing Conditions & Develop a Robust Process

- Reviewing how different cell types affect manufacturing process
- Identifying the different reagents required for varying cell types
- Overcoming differences to set up a robust manufacturing process

2.30 Group Discussion: Exploring Novel Combination Therapies Such as Checkpoint Blockades & Chemotherapy to Circumvent Tumour Defence Mechanisms & Improve CAR-T Efficacy

- Understanding how to go about combining checkpoint blockades with CAR-T cell therapy
- Analysing the dosing levels for chemotherapy and CAR-T cells when used in conjunction with each other
- Exploring how using combination therapy can help avoid tumour defence mechanisms

2.30 CAR-Treg Cell Therapy to Induce Tolerance in Liver Transplantation - Initial Insights From The LIBERATE Clinical Trial

- The LIBERATE study is a first-in-human Phase I/II clinical trial designed to evaluate the safety and activity of autologous CAR-Tregs directed to HLA-A2 (QEL-001) in promoting operational liver allograft tolerancE
- A safety cohort consisting of three patients found QEL-001 to be well tolerated at the protocol-defined dose range
- Comprehensive immunomonitoring of blood samples and liver biopsies indicates that QEL-001 was well tolerated, with evidence of engraftment, persistence, and stable suppressive function

Rupert Kenefeck, Senior Director, Translational Medicine, **Quell Therapeutics**

2.30 De-Risking The Journey from Bench to Patient

- Comprehensive, science-based solutions for cell therapy programs
- A flexible approach to accelerate the path to clinic and de-risk the manufacturing process
- From concept to market- off the shelf solutions with full journey support

Nuria Gomez Santos, Director Process & Analytical Development, **Catalent Cell and Gene Therapy**

3.00 Development & Clinical Readiness of Novel Armoured Adaptor CAR T-Cells for the Treatment of Solid Tumours

- Re-design of the CAR structure to recapitulate a more physiological architecture dramatically enhances potency, persistence and proliferation
- Chemokine receptor armouring results in better trafficking and infiltration into solid tumours, achieving high remission rates across a broad range of solid tumour models
- GMP-grade manufacture of these armoured adaptor CAR T-cells has been successfully achieved at scale using whole blood as the starting material

Marc Davies, Vice President, Research & Development, **Leucid Bio**

3.00 Insights into Clinical Pharmacology of Gamma Delta CAR-T Cell Therapies & Application in Solid Tumours & Autoimmune Disease

- Discuss key learnings from evaluation of 1st in class gamma delta CAR-T cell therapy in oncology
- Implications for realising therapeutic potential in autoimmune disease
- Tissue specific tropism for gamma delta CAR-T cell therapies and unlocking potential for addressing solid tumours

Blake Aftab, Chief Scientific Officer, **Adicet Bio**

3.00 Roundtable Discussion: Levers to Accelerate Manufacturing & Analytical Development of CAR-TCR Personalised Treatment

- Exploring shorter manufacturing processes
- Understanding rapid analytical methods
- Quick deviation management

Frederik De Vos, Senior Director Quality Operations, **Johnson & Johnson**

3.30 Discovery of Fully Human VH-Based CAR-T to Mitigate Immunogenicity & Enhance Efficacy

- Heavy-chain only CAR-T with lower immunogenicity and coded with short constructs in cell therapy
- Anti-BCMA-based CAR, discovered in partnership with Dana Farber Cancer Institute, delivers a potent and sustained anti-tumor efficacy in a mouse model
- Powerful platform for the discovery of fully human VH-based CAR enabled by NonaCarFxTM platform based on Harbour Mice®, the world's first clinically validated fully human HCAb transgenic mouse

Bradley Delaney, Scientist I, **Nona Biosciences**

3.30 Scalable 3D Tissue Models with Recirculating Fluid-Flow: An Automated Alternative to Animal Models

- We will build a fluid flow containing all of your cells of interest
- This flow will pass complex organoid models to assess off target or solid tumour effects
- We also carry out all of the traditional assays for you: flow cytometry, ELISA, immunohistochemistry etc.

Finola Cliffe, Chief Operations Officer, **Hooke Bio**

3.30 Silencing Lentiviral Vector Cargo Gene During Manufacturing

- Cargo gene expression can negatively impact LVV quality and titre, creating challenges in downstream processing and subsequent applications including cell therapies
- Our optimised gene-silencing system bypasses conventional methods for reducing gene expression, and shows improved production cell health, improved LVV infectious titres and recovery of otherwise non-recoverable producer cell lines
- The potential of this technology is of great benefit for any type of LVV manufacturing, including for in vivo therapies

Matthew Tridgett, Senior Scientist, Viral Cell Line Development, **OXGENE, A WuXi Advanced Therapies Company**

3.40 Afternoon Networking Break

Scientific Programme Day One | Wednesday, 26th February

Highlighting Different Cell Types & Their Advantages to Target Different Disease Indications & Increase Cell Therapy Efficacy

4.40 Overcoming Tumour Heterogeneity with MAGE-A4 Specific TCR-NK Cells: Development of Lead Product ZI-MA4-1

- Leveraging dual targeting of TCR-NK cells to potently attack heterogenous solid tumour cells
- Avoiding tumour escape mechanisms
- Delivering an allogeneic off-the shelf NK cell therapy

Luise Weigand, Head of Research, **Zelluna Immunotherapy**

5.10 A Stem Cell-Derived Vδ1 CAR γδ T-Cell Platform for Haematological & Solid Tumour Malignancies

- Vδ1 δδ T-cells have some distinct advantages over other cell types for tumour immunotherapy but are difficult to source in high numbers
- We are developing a platform technology to generate highly functional Vδ1 δδ T-cells in high numbers from stem cells
- The cells have shown high levels of activity in T-ALL models, which is further enhanced by a dual-CAR against T-ALL specific antigens

Stefanos Theroharis, Chief Executive Officer, **OneChain Immunotherapeutics**

Improving Tumour Models to Better Reflect the Effect of Cell Therapy on the Body & Improve Translation of Therapy

4.40 Distinct Tumor Immune Context in Relation to Differential Outcome to CAR T Cell Therapy

- Established tumor cell and microenvironment signatures associated with Axi-cel outcome
- Reverse-translational modeling of CAR T cell efficacy
- Predictive CAR T functionality measures to inform clinical outcomes

Rhine Shen, Senior Director, Translational Medicine, **Kite, A Gilead Company**

5.10 Understanding Mouse & Human CAR-T Cell *In Vivo* Models

- Exploring the benefits of mouse CAR-T cells
- Understanding the difference in human CAR-T cells vs mouse CAR-T cells
- Analysing TCR-T cell models and their differences

Katja Mohrs, Principal Scientist, **Regeneron**

Navigating Analytical Studies of Cell Products to Improve Product Quality Understanding & Meet Regulatory Expectations

4.40 Introducing Rapid Sterility Testing to Navigate Complexity of Personalised Medicine & Ensure High Quality of the Final Product

- Understanding what rapid sterility testing entails
- Assessing the impact of personalised medicine on sterility testing
- Optimising sterility testing to improve product quality and reduce long lead times

Shayoni Dutta, Data Science Manager, **GSK**

5.10 Analysing the Optimal Process for Tech Transfer to Reduce Manufacturing Timelines

- Investigating the need for tech transfer
- Reflecting on how and why tech transfer takes long and affects manufacturing timelines
- Tightening up the tech transfer process to improve manufacturing speed

Hemant Dhamne, Associate Director, Process Development, **Autolus**

5.40 Tracks Close

5.45 Drinks Reception & Scientific Poster Session

The poster session is the perfect opportunity for you to share your latest cutting-edge research and contribute to the conversation. So grab a drink and engage with colleagues, old friends and other authors to discuss the latest developments in the field.

6.45 End of Scientific Programme Day One

Scientific Programme Day Two | Thursday, 27th February

Key

Oncology Autoimmune

8.30 Check-In & Morning Coffee

Gwendolyn Binder
President, Science & Technology
Cabaletta Bio

9.20 **Chair's Opening Remarks**

Exploring Investment Trends & Understanding the Investment Landscape to Manage Expectations & Make Cell Therapy More Cost-Effective

Victor Dillard
Vice President, Strategy & Operations
Resolution Therapeutics

9.30 **Investment Landscape in Cell Therapy: a Macro(phage) Perspective**

- Beyond CAR-T and TCRs, investment opportunities across cell therapy
- What investors are looking for today in cell therapy
- Key trends in technology and manufacturing impacting investment behaviour in cell therapy

10.00 **Panel Discussion: Mergers, Acquisitions, Investments: Everything You Need to Know About What the Investors Are Looking For**

- Understanding the perspective of investors to understand what they are looking for
- Analysing pharma's needs to understand how to partner with them
- Having an open dialogue with investors to clarify what you are looking for and how they can help

Michael Bauer
Partner
Novo Holdings
Venture Investments

Kerstin Papenfuss
Head Pharma Team
Deep Science Ventures

10.45 Morning Networking Break

Scientific Programme Day Two | Thursday, 27th February

Discovery

Chair: Felix Lorenz, Chief Executive Officer/ Chief Scientific Officer, **Captain T Cell**

Outlining Approaches to Solid Tumours to Improve Efficacy & Durability in the Tumour Microenvironment

11.45 Enhancing TCR-T Cell Potency in Solid Tumours with Next-Generation Toolbox Technologies

- Enabling TCR-T cells to overcome the suppressive tumour microenvironment
- Augmenting T-cell performance and efficacy
- Reducing exhaustion to improve therapeutic durability

Felix Lorenz, Chief Executive Officer/ Chief Scientific Officer, **Captain T Cell**

12.15 Unlocking the Solid Tumour Landscape Through High-Sensitivity CAR-T

- Problem of current (low-sensitivity) CAR constructs
- MatchBio's proprietary platform for generating of novel high sensitivity CAR-T
- Application of MatchBio technology to unlock novel CAR-T targets in solid tumour

Omer Dushek, Founder, **MatchBio**

Clinical Development

Chair: Emilio Cosimo, Life Science Consultant, **Emilio Cosimo Consulting**

Tracking Cells *In Vivo* to Better Understand Durability & Mechanism of Action

11.45 Accurate Representation of the Human Immune System to Front-load Clinical Safety

- Understanding why model organisms have limited utility for cell therapy translation
- Front-loading safety and efficacy with in vitro models
- Translational data from model organisms

Hugh Salter, Chief Scientific Officer, **Anocca**

12.15 Group Discussion: Analysing Durability & Expansion Data to Gain an Understanding of What is Happening at a Cellular Level

- Reviewing cell data from clinical
- trials to understand durability level
- Assesssing expansion data to understand clinical outcomes
- Using this data to gain a better understanding of persistence at a cellular level

CMC, Process & Analytics

Chair: Frederik De Vos, Senior Director Quality Operations Advanced Therapies Platform, Johnson & Johnson

Translating Manufacturing for Other Cell Therapies & Indications to Increase Efficacy & Ensure Success During Dosing

11.45 Translation of PSC-Derived ProtoNK Platform: A Unique CMC Process & Targeting Metastasis of Paediatric Sarcoma

- Novelty of ProtoNK platform
- Development of our internal GMP manufacturing capability
- Moving towards clinical trial on lung and liver metastasis of Ewings sarcoma

Allen Feng, Founder & Chief Scientific Officer, **HebeCell Corp**

12.15 Novel CARs & New Applications – Implications for CMC, Process, & Analytics

- Manufacturing improvements needed given the increasing size of the Payload
- Ensuring patient safety as CAR TCR therapies are applied to less severe diseases

Farzin Farzaneh, Chief Scientific Officer & Co-Founder, **Virocell Biologics**

John Maher, Chief Scientific Officer, **Leucid Bio**

Renaud Vaillant, Chief Executive Officer, **Alaya.bio**

12.45 Networking Lunch

Scientific Programme Day Two | Thursday, 27th February

Outlining Approaches to Solid Tumours to Improve Efficacy & Durability in the Tumour Microenvironment

1.45 Exploring Advancements in CAR-T for Solid Tumours

- Overcoming the challenges of the tumour microenvironment
- Utilising the antigen presenting cell functions of gamma delta cells to elicit a secondary response
- An allogeneic approach

Jeff Liter, Founder & Chief Executive Officer, **Luminary Therapeutics**

2.15 Chimeric ILT-Receptor (CIR™) Allogeneic Technology Effectively Targets HLA-G+ Hematologic & Solid Tumours for Fit-for-Purpose Activation of NK Cells

- CIR™NK cells efficacy and safety in HLAG+ AML, hematologic and solid tumours (animal models data)
- Allogeneic technology to improve patient access and contain manufacturing costs
- Overview of the path to 2 IND with expected FIH clinical trial to start in 2027

Raphaël Ognar, President & Chief Executive Officer, **NKILT Therapeutics**

2.45 End of Discovery Track

Widening the Scope of Clinical Trials to Other Indications to Improve Clinical Trial Data & Guarantee Regulatory Approval

1.45 Accelerating Development of CAR-T for Autoimmune Disease Through Translational Medicine

- A translational talk highlighting CAR-T therapy in autoimmune disease
- Methods for evaluating activity and safety in various patient populations
- Recent and emerging data

Jenell Volkov, Senior Director Translational Medicine, **Cabaletta Bio**

2.15 Group Discussion: Optimising the Clinical Development of T-Cell Therapies In Autoimmune Diseases

- Transferring lessons from oncology to autoimmune diseases
- Emerging challenges

Marlene Carrasco Alfonso, Global Clinical Head Immunology Cell Therapy, **AstraZeneca**

Karin Enarsson Ringqvist, Senior Clinical Program Director, **AstraZeneca**

2.45 End of Clinical Development Track

Driving Automation in Manufacturing to Quicken CAR-T Production & Improve Scalability

1.45 Advances in the Promise of CAR-T Automation

- Supply challenges for CAR-T
- Automation benefits and options
- Enabling data to support CAR-T for autoimmune disease

Houman Dehghani, Vice President Process and Analytical Development, **Cabaletta Bio**

2.15 How to Launch & Scale Up Successfully a Commercial CAR-T Product

- Main challenges in launching and scaling up CAR-T manufacturing and patient supply
- Driving patient experience as a critical success factor for an effective launch and accelerated growth
- Automation as an enabler of accelerated growth

Birk Vanderweeën, Senior Vice President, Global Manufacturing & Supply, **Legend Biotech**

2.45 Development of a Scalable Upstream & Downstream CAR-T Manufacturing Workflow at the Multi-Litre Scale

- Intensifying CAR-T cell expansion via optimisation of perfusion parameters in stirred-tank bioreactors
- Scaling up CAR-T production from 250mL to 2L in stirred-tank bioreactors
- Characterisation of a scalable and automated solution for downstream CAR-T cell harvesting and buffer exchange

Pierre Springuel, PhD Candidate, **University College London**

3.15 **Afternoon Networking Break**

Exploring the CAR-TCR Landscape & Understanding the Progress in the Field to Propel Clinical Development

Rachel East
Research Analyst
Beacon

3.45 **A Landscape Overview of CAR & TCR Therapies**

- Reviewing current trends in the CAR and TCR therapy landscape
- Which platform technologies and innovations are developers utilising in an increasingly competitive space?
- Harnessing the insights of Beacon to accelerate the clinical development of your own cell therapy pipeline

Peggy Sotiropoulou
Chief Scientific Officer
T-knife Therapeutics
NEW DATA

4.15 **Rational Design & Synthetic Biology to Maximise Efficacy in T Cell Therapy**

- Understanding the challenges of T cell therapy for solid tumours
- Design multi-armoured TCR-T cells to improve durability and persistence
- Evaluating TCR-T cell efficacy using advanced tumor models

Gwendolyn Binder
President, Science & Technology
Cabaletta Bio

4.45 **Chair's Closing Remarks**

4.50 **End of Conference**

Our Partners

Programme Partners

Beacon by hansonwade
Catalent CELL & GENE THERAPY
Miltenyi Biotec
TERUMO BLOOD AND CELL TECHNOLOGIES
VIROCELL BIOLOGICS

Innovation Partners

hookebio
NONA BIOSCIENCES
WuXi Advanced Therapies

Hosting Partner

AKRON BIO

Exhibition Partners

aixial GROUP
CELLforCURE by SEQENS
chemometec
proteintech
SGS
TrakCel
TWIST BIOSCIENCE

Event Partner

BioCentriq
Fortrea
GemPharmatech
JC DISCOVERY

10TH ANNIVERSARY

CAR-TCR Summit

A Decade of Engineering a Disease Free World

SAVE THE DATE

September 23rd - 26th, 2025
Boston, MA

Register Your Interest